SGK
XERS icon

Steigerwald Gordon & Koch’s Xeris Biopharma Holdings XERS Stock Holding History

Steigerwald Gordon & Koch’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293 Hold
37
– – ﹤0.01% 741
2026
Q1 		$215 Hold
37
– – ﹤0.01% 755
2025
Q4 		$290 Hold
37
– – ﹤0.01% 887
2025
Q3 		$301 Buy
+37
New +$246 ﹤0.01% 787

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Steigerwald Gordon & Koch's XERS Position: Q2 2026 in Review

Steigerwald Gordon & Koch held its Xeris Biopharma Holdings (XERS) position steady in Q2 2026 at 37 shares worth $293. The position accounts for ﹤0.01% of the portfolio, ranked #741.

Steigerwald Gordon & Koch first reported a position in XERS in Q3 2025 and has held it in 4 quarters since. The position peaked at $301 in Q3 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Steigerwald Gordon & Koch held 37 shares of Xeris Biopharma Holdings worth $293 as of Q2 2026.
  • Steigerwald Gordon & Koch left its Xeris Biopharma Holdings share count unchanged in Q2 2026.
  • Xeris Biopharma Holdings made up ﹤0.01% of Steigerwald Gordon & Koch's portfolio in Q2 2026, its #741 holding.
  • Steigerwald Gordon & Koch first reported a position in Xeris Biopharma Holdings in Q3 2025 and has held it in 4 quarters since.
  • Steigerwald Gordon & Koch's Xeris Biopharma Holdings position peaked at $301 in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Steigerwald Gordon & Koch's 13F filing for Q2 2026, filed 23 Jul 2026.